BR112017018775A2 - métodos e composições para previsão da eficácia terapêutica dos tratamentos e prognósticos de câncer - Google Patents
métodos e composições para previsão da eficácia terapêutica dos tratamentos e prognósticos de câncerInfo
- Publication number
- BR112017018775A2 BR112017018775A2 BR112017018775A BR112017018775A BR112017018775A2 BR 112017018775 A2 BR112017018775 A2 BR 112017018775A2 BR 112017018775 A BR112017018775 A BR 112017018775A BR 112017018775 A BR112017018775 A BR 112017018775A BR 112017018775 A2 BR112017018775 A2 BR 112017018775A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- methods
- predicting
- compositions
- therapeutic efficacy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 238000004393 prognosis Methods 0.000 abstract 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
a presente invenção se refere, de uma forma geral, a métodos e composições para a previsão da eficácia terapêutica dos tratamentos contra o câncer e o prognóstico de câncer. a invenção divulga marcadores que estão associados com resultados favoráveis e desfavoráveis, respectivamente, em certos tratamentos contra o câncer e são úteis como marcadores de prognósticos para o câncer. os métodos envolvendo esses marcadores são divulgados para prever o benefício da terapia e prognóstico de câncer do resultado clínico para pacientes com câncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2015/058212 | 2015-04-15 | ||
| PCT/EP2015/058212 WO2016165765A1 (en) | 2015-04-15 | 2015-04-15 | Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis |
| PCT/EP2016/058061 WO2016166124A1 (en) | 2015-04-15 | 2016-04-13 | Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017018775A2 true BR112017018775A2 (pt) | 2018-04-17 |
| BR112017018775B1 BR112017018775B1 (pt) | 2023-09-19 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013938A (es) | Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer. | |
| BR112017016019A2 (pt) | método para tratamento de câncer, artigo para fabricação, e, kit. | |
| MY197809A (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
| CR20150217A (es) | Inhibidores de histona demetilasas | |
| BR112016017700A2 (pt) | método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit | |
| CL2015002807A1 (es) | Terapia de combinación | |
| BR112017000703A2 (pt) | métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit | |
| BR112015019995A2 (pt) | Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer | |
| EA201590554A1 (ru) | Ингибиторы глюкозилцерамид-синтазы | |
| BR112016012713A2 (pt) | Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento | |
| NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| EP3504348A4 (en) | USE OF GENOMIC SIGNATURES FOR PREDICTING THE REACTIVITY OF PATIENTS WITH PROSTATE CANCER TO POSTOPERATIVE RADIOTHERAPY | |
| BR112014024017A8 (pt) | Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3 | |
| CR20160289A (es) | Compuestos de inhibidor de autotaxina | |
| NI201400095A (es) | Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa. | |
| PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| BR112017012142A2 (pt) | método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama | |
| BR112016002000A2 (pt) | Diagnóstico e terapia de câncer envolvendo células-tronco tumorais | |
| CA2909625C (en) | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer | |
| BR112016019825A2 (pt) | anticorpos do fator bb do complemento | |
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| BR112016024332A2 (pt) | métodos para o tratamento, para a determinação dos compostos a serem utilizados, para a seleção de pacientes, para a monitoração da eficácia terapêutica, para a optimização da eficácia terapêutica, para a identificação de um biomarcador, artigo de fabricação, utilização de gdc-0941, gdc-0941 e um agente de terapia endócrina e composto para a utilização | |
| BR112018007671A2 (pt) | terapia de combinação para tratamento de malignidades | |
| BR112015010220A2 (pt) | métodos de utilização de biomarcadores para tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B25D | Requested change of name of applicant approved |
Owner name: GANYMED PHARMACEUTICALS GMBH (DE) ; TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/04/2016, OBSERVADAS AS CONDICOES LEGAIS |
|
| B25A | Requested transfer of rights approved |
Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) ; ASTELLAS PHARMA INC. (JP) |